• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

FDA approves Biofrontera's drug-device combo for sun-induced skin cancer

May 13, 2016 By Brad Perriello

BiofronteraBiofrontera (ETR:B8F) shares are up today after the said it won pre-market approval from the FDA for its drug-device combination treatment for a type of sun-induced skin cancer.

Leverkusen, Germany-based Biofrontera said the approval covers its Ameluz drug and BF-RhodoLED medical device for what it calls “photodynamic therapy” to treat mild to moderate actinic keratosis of the face and scalp.

Also known as solar keratosis, actinic keratosis is caused by damage to the skin by the sun’s ultraviolet rays. The Biofrontera treatment uses the Ameluz gel, which contains a photo-activated compound called 5-aminolaevulinic acid. The gel is applied to the keratosis lesions, then exposed after 3 hours to the red light from the BF-RhodoLED lamp, which causes the 5-aminolaevulinic acid to react with oxygen to create a toxic type of oxygen that kills the cancer cells, according to the European Medicines Agency.

Biofrontera won CE Mark approval in the European Union for Ameluz in 2011 and followed up with BF-RhodoLED CE Marking in 2012. The company said it expects to have the combination treatment on the U.S. market by September.

“We are extremely pleased with the FDA’s decision to approve Ameluz and BF-RhodoLED for the treatment of actinic keratosis. We expect early adoption from dermatologists as we showcase the response rates of guideline compatible field treatment, which is not covered by the label of competing technology,” CEO Hermann Luebbert said in prepared remarks. “The U.S. represents a large and growing market opportunity for the company and we have been eagerly preparing for the U.S. launch of Ameluz . We are excited about our growth prospects in the U.S., Europe, and other regions around the world and we look forward to expanding the indication for Ameluz to basal cell carcinoma first in the E.U., followed by the U.S.”

Biofrontera said it formed a U.S. subsidiary last year in anticipation of the FDA approval and is hiring ahead of the launch later this year.

Filed Under: Drug-Device Combinations Tagged With: Biofrontera

IN CASE YOU MISSED IT

  • Nuvo, Sheba Medical Center develop AI-powered gestational diabetes management platform
  • Verily’s Onduo, Sword Health collaborate on virtual diabetes care
  • Shareholder lawsuit over BD’s Alaris pumps recall moves forward
  • Embecta stock soars on first full-quarter results after BD spinoff
  • Abbott will spend $450M to up FreeStyle Libre production in Ireland

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS